Core Viewpoint - Meili Tianyuan Medical Health (02373.HK) announced a share buyback on December 1, 2023, spending HKD 2 million to repurchase 80,000 shares at a price range of HKD 24.6 to 25.34 per share [1] Summary by Category - **Company Actions** - The company executed a buyback of 80,000 shares at a total cost of HKD 2 million [1] - The repurchase price per share ranged from HKD 24.6 to 25.34 [1]

Core Viewpoint - The announcement highlights the confidence of the company's non-executive director, Ms. Li Fangyu, in the future development of the company through her acquisition of 41,500 shares, representing approximately 0.02% of the total issued shares as of the announcement date [1] Group 1: Share Acquisition - Ms. Li Fangyu increased her stake in the company by acquiring 41,500 ordinary shares through LIFY Management Holdings Limited in the open market [1] - The company repurchased 80,000 shares on December 1, 2025, for a total consideration of approximately HKD 2.0008 million, with an average transaction price of about HKD 25.01 per share [1] - From October 15, 2025, to the announcement date, the company has repurchased a total of 775,000 shares at a total cost of approximately HKD 22.6932 million [1] Group 2: Management Confidence - The board of directors believes that the current share price does not reflect the intrinsic value of the shares and the actual business prospects of the company [1] - The board expresses confidence that the share repurchase demonstrates management's strong belief in the long-term value of the enterprise, which is beneficial for enhancing the company's market value and shareholder return capabilities [1] - The share repurchase aligns with the overall interests of the company and its shareholders [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 美麗田園醫療健康產業有限公司 呈交日期： 2025年12月1日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | | 證券代號 (如上市) | 02373 | 說明 | | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | 事件 | | 已發行股份 ...

Core Viewpoint - The announcement highlights the confidence of the company's non-executive director, Li Fangyu, in the future development of the company through the acquisition of additional shares, indicating a positive outlook for the company's growth [1] Share Acquisition by Director - Li Fangyu has increased her stake in the company by acquiring 41,500 shares, representing approximately 0.02% of the total issued shares as of the announcement date [1] - The shares were purchased through LIFY Management Holdings Limited in the open market, reflecting her strong belief in the company's prospects [1] Share Buyback Program - The company has repurchased 80,000 shares on December 1, 2025, for a total consideration of approximately HKD 2.0008 million, with an average transaction price of about HKD 25.01 per share [1] - From October 15, 2025, to the announcement date, the company has repurchased a total of 775,000 shares at a total cost of approximately HKD 22.6932 million [1] Management's Perspective - The board of directors believes that the current share price does not reflect the intrinsic value of the shares and the actual business prospects of the company [1] - The share buyback is seen as a demonstration of management's confidence in the long-term value of the company, which is expected to enhance the capital market value and shareholder return capabilities [1] - The buyback aligns with the overall interests of the company and its shareholders [1]

Core Viewpoint - Meili Tianyuan Medical Health (02373.HK) has repurchased a total of 775,000 shares since October 15, 2025, with a total expenditure of approximately 22,693,170 HKD, indicating a strategic move to enhance shareholder value [1] Summary by Sections - **Share Repurchase Details** - On December 1, 2025, the company repurchased 80,000 shares at an average price of approximately 25.01 HKD per share, totaling around 200,000 HKD [1] - The total shares repurchased from October 15, 2025, to the announcement date amounts to 775,000 shares [1] - **Financial Implications** - The total expenditure for the repurchased shares is approximately 22,693,170 HKD, reflecting the company's commitment to returning capital to shareholders [1]

Core Viewpoint - The announcement highlights the increase in shareholding by non-executive director Li Fangyu, indicating strong confidence in the future development of the company [1] Summary by Relevant Sections - **Shareholding Increase**: Li Fangyu has informed the company of an increase of 41,500 shares in the company's ordinary shares, representing approximately 0.02% of the total issued shares as of the announcement date [1] - **Acquisition Method**: The shares were acquired through LIFY Management Holdings Limited in the open market [1] - **Confidence in Future**: The increase in shareholding reflects Li Fangyu's firm belief and high confidence in the group's future prospects [1]

美麗田園醫療健康產業有限公司 * 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何 部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 Beauty Farm Medical and Health Industry Inc. 茲提述本公司日期為2025年11月18日的公告（「11月18日公告」），內容有關收購若干 目標公司股權（構成本公司的關連交易）。除另有界定者外，本公告所用詞彙與11月 18日公告所界定者具有相同涵義。 本公司謹此就釐定對價時所考慮的基準提供以下額外資料： – 1 – （於 開 曼 群 島 註 冊 成 立 的 有 限 公 司） （股 份 代 號：2373） 關連交易 收購營運奈瑞兒品牌業務的股權 之補充公告 主席兼執行董事 (i) 目標公司經營的美容和保健門店的業務、營運及過往表現，包括： a. 對價與本集團過往可對比收購事項比例協調一致且相符，其市銷率及市盈 率分別介於0.3–0.9及4.4–6.0區間，符合本集團自2023年起所收購的其他門 店之過往市銷率與市盈率水平； b. 目 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何 部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 Beauty Farm Medical and Health Industry Inc. 美麗田園醫療健康產業有限公司 * （於 開 曼 群 島 註 冊 成 立 的 有 限 公 司） 本公司欣然公佈，本公司於2025年12月1日於市場購回80,000股本公司股份（「股份 回購」），總交易金額約2,000,780港元，交易平均價約每股25.01港元。自2025年10 月15日至本公告日期止期間，本公司已購回共775,000股股份，總對價約22,693,170 港元。 本公司董事（「董事」）會（「董事會」）認為，目前的股份成交價並不反映股份的內在價 值和本公司的實際業務前景。董事會相信，股份購回體現了管理層對企業長期價值 （股 份 代 號：2373） 自願公告 董事增持本公司股份；及 市場股份回購 本公告由美麗田園醫療健康產業有限公司（「本公司」，連同其附屬公司統稱「本集 團」）自願刊發。 董事增持本公司股 ...

Core Viewpoint - The company believes that the current share price does not reflect its intrinsic value and actual business prospects, indicating strong confidence in long-term value [1] Share Buyback Details - The company repurchased 80,000 shares on November 28, 2025, for a total consideration of approximately HKD 2.0074 million, with an average price of about HKD 25.09 per share [1] - From October 15, 2025, to the date of the announcement, the company has repurchased a total of 695,000 shares for approximately HKD 20.6924 million [1] Management's Perspective - The board of directors believes that the share buyback reflects management's confidence in the company's long-term value and is beneficial for enhancing market value and shareholder return capabilities [1] - The buyback is considered to be in the overall interest of the company and its shareholders [1]

Core Viewpoint - Meili Tianyuan Healthcare (02373) has repurchased shares, indicating management's confidence in the company's long-term value and business prospects [1] Summary by Sections Share Repurchase Details - The company repurchased 80,000 shares on November 28, 2025, for approximately HKD 2.0074 million, at an average price of HKD 25.09 per share [1] - From October 15, 2025, to the date of the announcement, the total shares repurchased amounted to 695,000, with a total cost of approximately HKD 20.6924 million [1] Management's Perspective - The board believes that the current share price does not reflect the intrinsic value of the shares and the actual business outlook of the company [1] - The share repurchase is seen as a demonstration of management's strong confidence in the company's long-term value, which is expected to enhance the group's market value and shareholder return capabilities [1] - The board asserts that the repurchase aligns with the overall interests of the company and its shareholders [1]